Connectivity Map-based docking of anti-diabetics targeting MAPK pathway kinases.
Thu, 24 Apr
|On Going Project
This study aims to integrate the Connectivity Map (CMap) approach with molecular docking to identify anti-diabetic compounds that can modulate MAPK pathway kinases. By bridging transcriptomic data with structural biology this research seeks to uncover novel interactions.
Time & Location
24 Apr 2025, 7:00 pm – 11:00 pm
On Going Project
About the event
✅ Background:
The MAPK (Mitogen-Activated Protein Kinase) pathway plays a significant role in insulin resistance, inflammation, and β-cell apoptosis—key hallmarks in the pathophysiology of Type 2 Diabetes Mellitus (T2DM). Targeting kinases such as ERK1/2, JNK, and p38 MAPK has shown therapeutic potential in regulating metabolic stress and improving insulin sensitivity.
The Connectivity Map (CMap) is a bioinformatics tool that links drugs, genes, and diseases through gene expression signatures. It helps predict which drugs can reverse or mimic disease-associated gene expression patterns—making it valuable for drug repurposing and target identification.
✅ Research Objective:
To use CMap to identify anti-diabetic or repurposable compounds that produce gene expression signatures opposing those of MAPK pathway dysregulation in diabetic models.
To dock the identified compounds with selected MAPK pathway kinases to evaluate binding affinity and interaction profiles.